Emergent BioSolutions shares undervalued, says Cowen at Cowen Cowen believes shares of Emergent BioSolutions is undervalued based on the potential of BioThrax alone and believes shares will outperform as its capacity expands. The firm also likes the company's strategy of pursuing growth through acquisition. Shares are Outperform rated.
News For EBS From The Last 14 Days
Check below for free stories on EBS the last two weeks.
Subscribe for More Information